Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PfSPZ-LARC2 (Sanaria Inc.)
- Development stage
- Unknown
- Lead developer
- Sanaria
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
PfSPZ-LARC2 is an experimental malaria vaccine regimen consisting of live, infectious *Plasmodium falciparum* sporozoites (PfSPZ) administered via direct venous inoculation in conjunction with the long-acting antimalarial drug pyrimethamine. This approach, known as Chemoprophylaxis Vaccination (CVac) or Long-Acting Chemoprophylaxis (LARC), utilizes the drug to arrest the parasite's development at the late liver stage or early blood stage, thereby preventing clinical malaria while allowing the host's immune system to be exposed to a broad array of liver-stage antigens. This exposure induces potent, protective T-cell responses. Developed by Sanaria in collaboration with the University Hospital Tübingen, PfSPZ-LARC2 is designed to provide durable, high-level protection against malaria with a simplified dosing schedule compared to earlier CVac iterations.
- Other names
- Plasmodium falciparum sporozoite long-acting chemoprophylaxis 2 vaccinePfSPZ-LARC2 vaccinePfSPZ-LARC-2 vaccinePfSPZ-LARC 2 vaccinePfSPZ-CVac (pyrimethamine)
02
Targets
Nucleotide synth (Nucleotide synthesis enzymes)
Beyond the preview
Go deeper on PfSPZ-LARC2 (Sanaria Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PfSPZ-LARC2 (Sanaria Inc.).